🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 80 of 116

  1. erlotinib and bexarotene

    LIGAND PHARMACEUTICALS INC

    Carcinoma, Non-small-cell Lung

    phase 2 small molecule completed

    1 trial

  2. everolimus

    United Therapeutics Europe Ltd

    Malignant Peripheral Nerve Sheath Tumors

    phase 2 small molecule completed

    1 trial

  3. evorpacept

    ALX ONCOLOGY HOLDINGS INC

    Head and Neck Cancer

    phase 2 small molecule active

    2 trials

  4. experimental group x-MAP

    The First People's Hospital of Lianyungang

    Metastatic Colorectal Cancer (mCRC)

    phase 2 other active

    1 trial

  5. farletuzumab ecteribulin

    Bristol-Myers Squibb Australia Pty Ltd

    Metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  6. farletuzumab ecteribulin, LENVIMA 4 mg hard capsules, LENVIMA 10 mg hard capsules

    Eisai Co.,

    Solid tumors in 4 tumor types: platinum resistant ovarian cancer, triple-negative breast cancer (TNBC), endometrial cancer (EC), and non-small cell lung cancer adenocarcinoma; NSCLC).

    phase 2 small molecule active

    1 trial

  7. favezelimab, quavonlimab, Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Lenvatinib

    Merck Sharp and Dohme

    Stage IV non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  8. forodesine HCl

    Biocryst

    Chronic Lymphocytic Leukemia (CLL)

    phase 2 small molecule completed

    1 trial

  9. forodesine hydrochloride

    Biocryst

    Lymphoma

    phase 2 small molecule completed

    2 trials

  10. forodesine hydrochloride (BCX-1777)

    Biocryst

    Leukemia, Lymphocytic, Chronic

    phase 2 small molecule completed

    1 trial

  11. forodesine hydrochloride (BCX-1777)

    Biocryst

    B-cell Acute Lymphoblastic Leukemia

    phase 2 small molecule completed

    1 trial

  12. forodesine hydrochloride (BCX-1777)

    Biocryst

    Leukemia, T-Cell

    phase 2 small molecule completed

    1 trial

  13. fostamatinib

    RIGEL PHARMACEUTICALS INC

    Lymphoma

    phase 2 small molecule completed

    1 trial

  14. fruquintinib

    Takeda

    Colon Cancer

    phase 2 small molecule active

    1 trial

  15. furmonertinib

    Sun Yat-sen University

    Non-small Cell Lung Cancer Metastatic

    phase 2 small molecule completed

    1 trial

  16. ganetespib

    United Therapeutics Europe Ltd

    Malignant Peripheral Nerve Sheath Tumors (MPNST)

    phase 2 small molecule completed

    1 trial

  17. gemcitabine

    Yung NA

    Muscle Invasive Bladder Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  18. gemcitabine and cisplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  19. gemcitabine and oxaliplatin.

    The First People's Hospital of Lianyungang

    Gallbladder Carcinoma

    phase 2 small molecule active

    1 trial

  20. genexolPM + cisplatin

    Solid Biosciences

    Locally Advanced Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  21. hyperbaric oxygen

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 small molecule active

    1 trial

  22. imvotamab

    ADC Therapeutics SA

    Non-Hodgkin Lymphoma

    phase 2 small molecule terminated

    1 trial

  23. indibulin

    Alaunos Therapeutics

    Advanced Solid Tumors

    phase 2 small molecule active

    2 trials

  24. infusion of MYOCET

    Teva Pharma GmbH

    Cerebral Lymphoma B Cell Refractory

    phase 2 small molecule terminated

    1 trial

  25. inhaled delta-8-THC 300mcg or 600mcg per dose

    Teva Pharma GmbH

    Cancer

    phase 2 small molecule terminated

    1 trial

  26. interleukin-4 PE38KDEL cytotoxin

    NEUROCRINE BIOSCIENCES INC

    Brain and Central Nervous System Tumors

    phase 2 mab completed

    1 trial

  27. intravenous infusion (IV) of Adebrelimab (ADE)

    The First People's Hospital of Lianyungang

    Advanced Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  28. ipatasertib

    United Therapeutics Europe Ltd

    Solid Tumor

    phase 2 small molecule active

    1 trial

  29. ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab

    Second Affiliated Hospital of Soochow University

    Liver Cancer

    phase 2 small molecule active

    1 trial

  30. irradiation

    Ultragenyx UK Limited

    Brain Neoplasms

    phase 2 other active

    1 trial

  31. ivosidenib and nivolumab

    Agios Netherlands B.V.

    Advanced Solid Tumor

    phase 2 small molecule completed

    1 trial

  32. lenalidomide combined with rituximab

    The First People's Hospital of Lianyungang

    Diffuse Large B Cell Lymphoma

    phase 2 small molecule active

    1 trial

  33. leucovorin, oxaliplatin, docetaxel, S-1

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric Cancer

    phase 2 small molecule active

    1 trial

  34. linrodostat mesylate; IDO1 inhibitor, linrodostat mesylate; IDO1 inhibitor, Ipilimumab, Relatlimab intravenous, OPDIVO 10 mg/mL concentrate for solution for infusion., linrodostat mesylate; IDO1 inhibitor, Ipilimumab

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Malignant Tumors

    phase 2 small molecule active

    1 trial

  35. long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations

    BEONE MEDICINES AUS PTY LTD

    Colorectal Neoplasms

    phase 2 other active

    1 trial

  36. lurbinectedin, JEMPERLI 500 mg concentrate for solution for infusion

    The George Institute

    Advanced/Recurrent Endometrial Cancer Patients with Disease Progression after Prior Therapy with Platinum-based Chemotherapy

    phase 2 small molecule active

    1 trial

  37. lymphokine-activated killer cells

    LISATA THERAPEUTICS, INC.

    Brain and Central Nervous System Tumors

    phase 2 mab terminated

    1 trial

  38. mFOLFOX6 + BIBF 1120

    Galmed Pharmaceuticals

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  39. mFOLFOXIRI

    The First People's Hospital of Lianyungang

    Locally Advanced Rectal Cancer

    phase 2 small molecule active

    1 trial

  40. mRNA-4157, BCG VACCINE

    Merck Sharp and Dohme

    Bladder cancer

    phase 2 small molecule active

    1 trial

  41. megestrol acetate oral suspension + serplulimab + SOX

    The First People's Hospital of Lianyungang

    Stage III Gastric Cancer

    phase 2 small molecule active

    1 trial

  42. mitoxantrone liposome 16 and azacitidine

    NovaBridge Biosciences

    Angioimmunoblastic T-cell Lymphoma

    phase 2 small molecule active

    1 trial

  43. nab-paclitaxel

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer

    phase 2 small molecule active

    1 trial

  44. nal-IRI /Experimental

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Metastatic Gastric Adenocarcinoma

    phase 2 small molecule active

    1 trial

  45. nanoliposomal irinotecan

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head & Neck Cancer

    phase 2 small molecule completed

    1 trial

  46. nanoparticle albumin-bound paclitaxel/carboplatin

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  47. nedaplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Central Nervous System Tumors

    phase 2 small molecule active

    1 trial

  48. neoadjuvant anti-PD-1

    Shanghai Chest Hospital

    Esophageal Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.